Arcturus Therapeutics reports Q3 EPS (26c), consensus ($1.22)

Reports Q3 revenue $41.7M, consensus $36.6M. “I am thrilled about the approval of KOSTAIVE for the COVID-19 JN.1 strain in Japan and for the continued success of the STARR platform in multiple Phase 3 trials, underscoring CSL and Arcturus’ commitment to deliver disruptive technologies for protection against respiratory viral diseases,” said Joseph Payne, President & CEO of Arcturus Therapeutics (ARCT). “I am pleased that both of our flagship mRNA therapeutic programs, ARCT-032 and ARCT-810, are on track for interim Phase 2 proof-of-concept clinical data in the first half of 2025. These studies allow us to evaluate lung function improvement in individuals with cystic fibrosis, and meaningful biomarker changes in individuals with OTC deficiency.”